Skip to content

Mineralys Therapeutics Inc

MLYS

Latest QuantConomy context for MLYS: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.

Asset class
stock
Primary venue
NASDAQ
Recent signals
3
SEC filings
20
Asset profile

Mineralys Therapeutics Inc

QuantConomy has a structured record for MLYS. More descriptive asset metadata will appear here when the platform record includes it.

Symbol
MLYS
Name
Mineralys Therapeutics Inc
Coverage
3 market/data records
Sources
fmp alphavantage alpaca sec nasdaq
Latest signal rows

Recent signals for MLYS

Scored rows are pulled from the same signal API used by the digests.

Signal Direction Score Observed Reason
insider trade
large sale
slightly bearish
38
Jun 30, 10:48 PM Congleton Jon sold MLYS shares ($1.50M) - 58,000 shares - [weak slightly bearish signal]
insider trade
large sale
slightly bullish
30
Jun 30, 10:47 PM Warren Eric exercised options for MLYS shares ($1.38M) - 104,124 shares - [very weak slightly bullish signal]
earnings
earnings release
neutral
40
Mar 12, 12:00 AM MLYS filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-03-12. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read).

EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).

PRICE signals are experimental: realized 30-day directional accuracy is ~18% (short-horizon price moves tend to mean-revert). They are automatically down-weighted in composite scores but served raw here. Do not use them as standalone trade advice.

Market coverage

Market Exchange Source Asset record
MLYS NASDAQ fmp Mineralys Therapeutics, Inc.
MLYS NASDAQ alphavantage Mineralys Therapeutics Inc
MLYS NASDAQ alpaca Mineralys Therapeutics, Inc. Common Stock

Recent insider transactions

Buys, last 90d
0
Sells, last 90d
2
Rows
20
Date Insider Role Type Shares Price Value Filing
Jun 30, 2026 Congleton Jon Chief Executive Officer sale 58,000 $25.94 $1,504,706 4 on EDGAR
Jun 26, 2026 Warren Eric Chief Commercial Officer exercise 104,124 $13.24 $1,378,602 4 on EDGAR
Jun 17, 2026 Karydas Daphne Insider exercise 3,000 $12.02 $36,060 4 on EDGAR
Jun 15, 2026 Rodman David Malcom Chief Medical Officer exercise 3,542 $10.20 $36,128 4 on EDGAR
Jun 10, 2026 Rodman David Malcom Chief Medical Officer exercise 2,170 $16.00 $34,720 4 on EDGAR
May 18, 2026 Rodman David Malcom Chief Medical Officer exercise 417 $15.44 $6,438 4 on EDGAR
May 11, 2026 Rodman David Malcom Chief Medical Officer exercise 2,171 $16.00 $34,736 4 on EDGAR
Apr 17, 2026 Rodman David Malcom Chief Medical Officer exercise 416 $15.44 $6,423 4 on EDGAR
Apr 13, 2026 Congleton Jon Chief Executive Officer sale 15,730 $26.83 $421,979 4 on EDGAR
Apr 13, 2026 Rodman David Malcom Chief Medical Officer exercise 6,349 $1.08 $6,857 4 on EDGAR
Apr 9, 2026 Rodman David Malcom Chief Medical Officer exercise 2,170 $16.00 $34,720 4 on EDGAR
Mar 31, 2026 Congleton Jon Chief Executive Officer sale 19,364 $25.50 $493,794 4 on EDGAR
Mar 31, 2026 Karydas Daphne Insider exercise 3,000 $12.02 $36,060 4 on EDGAR
Mar 27, 2026 RA CAPITAL MANAGEMENT, L.P. Director purchase 310,700 $23.67 $7,354,269 4 on EDGAR
Mar 17, 2026 Rodman David Malcom Chief Medical Officer exercise 417 $15.44 $6,438 4 on EDGAR
Mar 12, 2026 Rodman David Malcom Chief Medical Officer exercise 6,348 $1.08 $6,856 4 on EDGAR
Mar 9, 2026 Rodman David Malcom Chief Medical Officer exercise 2,171 $16.00 $34,736 4 on EDGAR
Warren Eric Chief Commercial Officer 3 on EDGAR
Feb 19, 2026 Levy Adam Scott CFO and Secretary grant 39,900 $0.00 $0 4 on EDGAR
Feb 19, 2026 Congleton Jon Chief Executive Officer grant 140,900 $0.00 $0 4 on EDGAR

Source: SEC filings via QuantConomy. Not investment advice.

Get the data

Query MLYS context like a database.

These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.

No spam, no noise. Just the launch and the occasional preview.

More: All insider trades · How to read a Form 4 · API access